Fig. 3
From: Ceritinib is a novel triple negative breast cancer therapeutic agent
Ceritinib inhibits WNT/β-catenin signaling pathway and cancer stem cell markers. (A) Ceritinib treatment inhibited major WNT signaling proteins in time course in MDA-MB 453 cells and (B) MFM223 cells. Ceritinib treatment also significantly suppressed ABC transporters ABCG2 and stem marker ALDH1/2 in MDA-MB 453 cells (C) and MFM223 cells (D) in a time dependent manner. Vinculin was used as a protein loading control. (E) The proposed model